TY - JOUR
T1 - Drug discovery for overcoming chronic kidney disease (CKD)
T2 - Pharmacological effects of mineralocorticoid-receptor blockers
AU - Nishiyama, Akira
AU - Hitomi, Hirofumi
AU - Rahman, Asadur
AU - Kiyomoto, Hideyasu
PY - 2009
Y1 - 2009
N2 - There is increasing evidence demonstrating that the renoprotective effects of mineralocorticoid receptor (MR) blockade are independent of the effects exerted by renin-angiotensin inhibitors. MR is expressed not only in tubular cells but also in other renal cells including glomerular mesangial cells, podocytes, and renal interstitial fibroblasts. Animal experiments have shown that MR blockers prevent aldosterone-induced proteinuria, glomerular injury, and tubulointerstitial fibrosis. In vitro studies have also demonstrated that MR blockers inhibit aldosterone-induced renal cell damage. Recent clinical studies have shown that treatment with MR blockers attenuates the development of proteinuria in patients with chronic kidney disease (CKD) and hypertension, independent of changes in blood pressure. In some cases, MR blockers elicit potent renoprotective effects in conditions where aldosterone levels are not elevated. These data suggest that treatment with MR blockers may possibly present an effective therapeutic strategy for patients with CKD.
AB - There is increasing evidence demonstrating that the renoprotective effects of mineralocorticoid receptor (MR) blockade are independent of the effects exerted by renin-angiotensin inhibitors. MR is expressed not only in tubular cells but also in other renal cells including glomerular mesangial cells, podocytes, and renal interstitial fibroblasts. Animal experiments have shown that MR blockers prevent aldosterone-induced proteinuria, glomerular injury, and tubulointerstitial fibrosis. In vitro studies have also demonstrated that MR blockers inhibit aldosterone-induced renal cell damage. Recent clinical studies have shown that treatment with MR blockers attenuates the development of proteinuria in patients with chronic kidney disease (CKD) and hypertension, independent of changes in blood pressure. In some cases, MR blockers elicit potent renoprotective effects in conditions where aldosterone levels are not elevated. These data suggest that treatment with MR blockers may possibly present an effective therapeutic strategy for patients with CKD.
KW - Aldosterone
KW - Chronic kidney disease (CKD)
KW - Eplerenone
KW - Kidney
KW - Mineralocorticoid receptor (MR)
UR - http://www.scopus.com/inward/record.url?scp=58649092641&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=58649092641&partnerID=8YFLogxK
U2 - 10.1254/jphs.08R12FM
DO - 10.1254/jphs.08R12FM
M3 - Short survey
C2 - 19151533
AN - SCOPUS:58649092641
VL - 109
SP - 1
EP - 6
JO - Journal of Pharmacological Sciences
JF - Journal of Pharmacological Sciences
SN - 1347-8648
IS - 1
ER -